# Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis

> **NCT00125333** · PHASE1,PHASE2 · COMPLETED · sponsor: **Anesiva, Inc.** · enrollment: 75 (—)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** NF-kappaB Decoy

## Key facts

- **NCT ID:** NCT00125333
- **Lead sponsor:** Anesiva, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 75 (—)
- **Last updated:** 2008-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00125333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00125333, "Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00125333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*